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Abstract: Between 1958 and 1961, the drug Thalidomide was prescribed in the UK as a treatment for
morning sickness. It caused severe birth defects. Thalidomide survivors are now experiencing a range
of secondary health problems, including depression and anxiety. Internationally, it is estimated that
40% to 50% of Thalidomide survivors have recently experienced common mental health problems.
The aim of this study was to gather information about the pattern of symptoms of depression and
anxiety amongst UK Thalidomide survivors. A cross-sectional postal survey of 182 UK Thalidomide
survivors, which used Patient Health Questionnaire (PHQ-9) and General Anxiety Disorder Scale
(GAD-7) to measure self-reported depression and anxiety, was conducted. Data were first analysed
using descriptive statistics. A point-biserial correlation was used to examine whether being unable to
work was associated with higher depression and anxiety scores. Prevalence of all levels of depression
and anxiety was higher amongst the Thalidomide survivors than the general UK population but
broadly similar to other groups of adults with disabling conditions. Being unable to work was
associated with higher depression and anxiety scores. More research is needed to understand the
relationship between early acquired physical disability and depression, in particular the implications,
over the life course, of secondary health problems and changing social roles.
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1. Introduction
Between 1958 and 1961, the drug Thalidomide was prescribed in the UK as a sup-
posedly safe treatment for morning sickness. However, when taken in the first trimester,
it caused severe birth defects, which together are referred to as Thalidomide Embryopathy
(TE). Dysmelia (missing, short and/or deformed limbs) and associated damage to joints are
the most common features of TE, but the drug also caused a wide variety of other birth de-
fects, including damage to eyes, ears and internal organs, and facial disfigurement [1]. It is
estimated that between 10,000 and 25,000 Thalidomide babies were born worldwide [2,3]
(Lenz 1988, Johnson et al. 2018). In the UK, the figure was around 2000. As many as three
quarters died soon after birth or in early childhood, but the UK Thalidomide survivors
who reached adulthood are expected to have a near normal life expectancy. Across the
world, around 5000 Thalidomide survivors are still living with the consequences of the
drug, and while TE is regarded as a non-progressive condition, it is not static. Thalidomide
survivors are now experiencing a range of Thalidomide-related health problems which are
being layered onto, and interacting with, their original impairments, causing further loss
of function [4]. This loss of function and the consequences it has for independence have
profound implications for Thalidomide survivors’ mental well-being [5]. The international
literature [4] suggests that common mental health problems are the second most frequently
reported health issue for Thalidomide survivors, after musculoskeletal problems.
Although estimates vary, based on the nature of the studies and measures used, the ev-
idence from Germany [6], Brazil [7] and Japan [8] suggests that between 40% and 50% of
Thalidomide survivors have recently experienced mental health problems. In 2015, a Health
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and Well-being survey of UK Thalidomide survivors found that almost half the respondents
reported they were currently or had recently experienced depression and/or anxiety [5],
but little is known about the severity of depression and anxiety being experienced.
In the wider disability literature, the link between disability and depression is well
established. There is also substantial evidence about the possible reasons for this associa-
tion, notably that people with disabilities are likely to experience the negative effects of:
lower levels of social integration; activity limitations, barriers to employment; financial diffi-
culties; and both structural and interpersonal discrimination [9–12]. However, what is less
well understood is the cumulative impact of these disadvantages, especially for those with
early acquired impairments, and how this impact might change over the life course [13,14].
Thalidomide survivors are a relatively small group, and the historical and social context
of their lives is unique. However, because they are a cohort who are ageing together,
understanding their experience may contribute to our broader understanding of disability
and depression over the life course.
The aim of this study was to gather information about the pattern of symptoms
of depression and generalised anxiety amongst UK Thalidomide survivors, and where
possible, make comparisons with both the general population and other groups with early
acquired disabilities. It was part of a larger body of work which subsequently developed
and tested a peer-led intervention for Thalidomide survivors experiencing low mood.
2. Materials and Methods
The study design was a cross-sectional postal survey of all UK Thalidomide survivors.
It received ethical approval from the Department of Health Sciences Research Governance
Committee at the University of York, on 2 July 2018. The survey questionnaire was
developed in partnership with Thalidomide survivors, and staff and trustees from the UK
Thalidomide Trust. The questionnaire had five sections, three of which are relevant to this
paper (self-reported health status and open-ended questions related to well-being were not
included in the analysis):
Section 1: Biographical Information-Three questions about gender, home circum-
stances, and work situation. Information about age was not sought because the great
majority of Thalidomide survivors were aged between 56 and 59 at the time of the survey.
Section 2: Depression-Self-reported depression severity was measured using the
Patient Health Questionnaire (PHQ-9) [15]. PHQ-9 explores how the person has felt in
the last two weeks and consists of nine questions with four possible responses to each
question. The responses are scored from 0 to 3, giving an overall score range of 0–27.
There are five scoring levels indicative of severity of depression symptoms: 0 to 4 = no
depression; 5 to 9 = mild depression; 10–14 = moderate depression; 15 to 19 = moderately
severe depression; and 20 to 27 = severe depression.
Section 3: Generalised Anxiety-Self-reported anxiety was measured using the General
Anxiety Disorder Scale (GAD-7) [16]. This measure explores how the person has felt in the
last two weeks and consists of seven questions with the four possible responses scored
from 0 to 3, giving an overall score range of 0–21. There are four scoring levels that classify
severity of anxiety symptoms reported: 0 to 4 = no anxiety; 5 to 9 = mild anxiety; 10 to
14 = moderate anxiety; and 15 to 21 = severe anxiety.
The survey questionnaire (together with a letter from the Trust, an information sheet
and a freepost reply envelope), was sent by the Thalidomide Trust to 413 UK Thalidomide
survivors. Those who: lacked capacity; were currently being treated for severe mental illness;
or lived outside the UK were excluded (n = 53). The survey was distributed by post in early
September 2018. A reminder email was sent in early October. It was also publicised on the
Thalidomide Trust website and via social media. When the survey closed in mid-October,
182 completed questionnaires had been received, giving a response rate of 44%.
The survey data were entered into an Excel spreadsheet. Each response was given an
identification number. The anonymised data were then transferred to SPSS (IBM, Armonk,
NY, USA) for analysis. The data were first analysed using descriptive statistics, and the
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results for the three validated questionnaires were then compared, where possible, with the
general population or other groups with early acquired disabilities. Previous research [5] had
suggested that being unable to work was having a negative impact on the mental well-being
of UK Thalidomide survivors. A binary variable (unable to work/working or chosen not to
work) was created. We examined (using a point-biserial correlation) whether being unable
to work was associated with higher depression (PHQ-9) and anxiety (GAD-7) scores.
3. Results
Of the 182 survey respondents, 92 (50.5%) were women, 80 (44.5%) were men and
10 (5%) did not give their gender. The UK population of thalidomide survivors is equally
split between women and men, and so there was a slight bias towards women in the survey
sample. In terms of living circumstance, around two-thirds lived with their partner/spouse
or their partner/spouse and other family members (117/65.4%), and almost a quarter
(42/23.5%) lived alone. Three respondents did not provide data. For work situation,
just over a third (61/34.2%) said they were unable to work because of their disability or
health problems, and nearly a third said they had chosen not to work in order to preserve
their health/functioning (40/22.4%) or for family/personal reasons (12/6.7%). Twenty-two
(12.3%) were working full time, 18 (10%) were working part time and six (3.4%) said they
were not working but would like to. Nineteen respondents (10.9%) recorded their work
situation as “Other”, which, from the descriptions provided, included those who were on
sick leave, or had retired early or had family caring responsibilities. Four respondents did
not provide data. For the further statistical analysis, these work categories were recoded as
0 = unable to work (61/34.1%) and 1 = all other categories (118/65.9%).
3.1. Depression
Analysis of the PHQ-9 scores showed that 75 respondents (43.4%) had no symptoms
of depression. Just over a quarter (27.2%, n = 47) had symptoms of mild depression. Almost
a third reported symptoms of moderate to very severe depression: 23 respondents (13.3%)
moderate depression; 16 (9.2%) severe depression; and 12 (6.9%) very severe depression
(see Table 1). On average, male respondents had higher PHQ-9 scores (more depression
symptoms; M = 8.08, SD = 7.54) than female respondents (M = 6.64, SD = 6.06) but this
difference was not statistically significant, F (1, 165) = 1.84, p = 0.177 (ten participants who
did not give their gender were excluded). The overall mean PHQ-9 score for the sample
was 7.32, SD = 6.85. Note that due to missing data, PHQ-9 scores were not available for nine
participants, who were not included in these analyses. Further analysis also showed that
being unable to work was associated with higher depression (PHQ-9) scores (rpb = −0.463,
p = 0.000) (nine respondents had missing data and were excluded).
Although PHQ-9 has been widely used in both clinical and population-based settings,
an eight-item version without the final question about self-harm (PHQ-8) has since been
developed for use in large epidemiological studies [17] where mental health follow-up is
not feasible. A major study by Arias de la Torre et al. (2021) [18] used PHQ-8 to estimate
the prevalence and age pattern of depression in the UK population. They found that in the
45-to-59 age group: 12% had mild depressive symptoms; 5.1% had moderate depressive
symptoms; and 5.3% had severe depressive symptoms. They also found that depressive
symptoms were higher amongst women than men. This suggests that the prevalence of
all levels of self-reported depression is likely to be much higher amongst the Thalidomide
survivors than the general UK population, but unlike the general population, there was no
significant difference between men and women.
It was difficult to find comparative data on PHQ-9 (or PHQ-8) scores for other groups
with early acquired disability. However, a German study [19] of depression in the general
population, which also used PHQ-9, found a strong positive association between depression
and disability. Jensen et al. (2014) [20] used PHQ-9 to measure depression amongst people
with Spinal Cord Injury (SCI), Multiple Sclerosis (MS) and Muscular Dystrophy (MD).
Whilst this study included adults of all ages, the mean age for their participants was
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52.6, i.e., relatively close to the age group for UK Thalidomide survivors (i.e., between
56 and 59 years at the time of the survey). The pattern of PHQ-9 scores in the study is
broadly similar to that of Thalidomide survivors, although the proportion of Thalidomide
survivors in the “Moderately Severe” and “Severe” groups is almost double (9% compared
to 16.1%). Table 1 shows the results for both this study and Jensen et al. (2014).
Table 1. PHQ-9 results for Thalidomide survivors and comparator group.
Level of Depression
Thalidomide Survivors * Combined % for
SCI, MS and MD
Number Percentage
None (0–4) 75 43.4% 44%
Mild (5–9) 47 27.2% 32%
Moderate (10–14) 23 13.3% 15%
Moderately Severe (15–19) 16 9.2% 6%
Severe (20–27) 12 6.9% 3%
Total 173 100%
Missing 9
* From Jensen et al. 2014: SCI = Spinal Cord Injury; MS = Multiple Sclerosis; MD = Muscular
Dystrophy.
3.2. Generalised Anxiety
Analysis of the GAD-7 scores found that three quarters of respondents had no symp-
toms of anxiety (n = 91/51.7%) or only mild symptoms (n = 41/23.3%). The remaining
quarter had symptoms of moderate to severe anxiety: 26 respondents (14.8%) moderate
anxiety; and 18 (10.2%) had severe anxiety (see Table 2). This compares to estimates of 5%
and 1%, respectively, for the general UK population [21]. On average, male respondents
had higher GAD-7 scores (more anxiety symptoms; M = 6.66, SD = 6.63) than female
respondents (M = 5.35, SD = 4.92), but this difference was not statistically significant,
F (1, 165) = 2.11, p = 0.148 (excluding the ten participants who did not give their gender).
The overall mean GAD-7 score for the sample was 5.95, SD = 5.87. Note that, due to missing
data, GAD-7 scores were not available for six participants who were not included in this
analysis. Further analysis also showed that being unable to work was associated with
higher anxiety (GAD-7) scores (rpb = −0.348/p = 0.000) (nine respondents had missing
data and were excluded). Sixty-five participants (38.70%) had no symptoms of either
depression or anxiety; 21 had only depressive symptoms and 9 had only anxiety symptoms.
The majority of those reporting symptoms were therefore reporting symptoms of both
depression and anxiety.
Table 2. GAD-7 results for Thalidomide survivors.
Level of Anxiety Number Percentage
None (0–4) 91 51.7%
Mild (5–9) 41 23.3%
Moderate (10–14) 26 14.8%




This is the first study of the prevalence and severity of depression and anxiety amongst
UK Thalidomide survivors. The findings suggest that the prevalence of all levels of
self-reported depression and generalised anxiety are higher amongst the Thalidomide
survivors than the general UK population, with more than half reporting symptoms of
depression and just under half reporting symptoms of generalised anxiety. However,
the prevalence of symptoms of depression is broadly similar to other groups of adults with
disabling conditions. Although there is substantial evidence that people with disabilities
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are more likely to report depressive symptoms, the relationship between physical disability
and depression is complex. Much of the literature focusses on older adults, and our
understanding of this relationship in working-age adults, especially those with early
acquired impairments, is still developing [9,12,13]. Kemp and Mosqueda (2004) [22] made
the point that whilst rates of depression are higher amongst people with disabilities,
impairment alone does not cause depression. Rather, it is the social and psychological
consequences of impairment that lead to higher levels of depressive symptoms.
A few studies have examined functional impairment (as measured by Activities
of Daily Living/Instrumental Activities of Daily Living (ADL/IADL) and prevalence
of depression. A UK study by Meltzer et al. (2012) [23] found a higher prevalence of
depression and mixed depression/anxiety amongst people with disabilities compared to
people who do not have impairments with disabling consequences, a finding supported
by a more recent study of middle-aged and older Chinese adults [24]. The literature
on ageing with TE also suggests that restricted physical function (especially decline in
physical function) is one of the factors highlighted as contributing to higher levels of
common mental health problems amongst Thalidomide survivors [5,25,26]. Social isolation,
pain, unemployment, and the need for care and personal assistance are also highlighted,
although clearly these factors are likely to be linked to and influenced by physical function.
Our study also found that being unable to work was associated with higher depression and
anxiety scores, which appears to reinforce the association between being unable to work
and symptoms of depression reported in the wider literature on TE. However, there could
be several underlying and interrelated causes for this. Not working may lead to some
Thalidomide survivors feeling more socially isolated, and the loss of an important social
role may have psychological consequences. However, those who are unable to work may
also have more severe secondary health problems, which may in turn be associated with
higher levels of pain.
There are differing views about whether people with early acquired impairments have
higher subjective well-being than those disabled later in life [9,27–30]. However, there is
now growing evidence of the cumulative impact of disability on mental health [10,12,13].
Stress perspectives [31,32] suggest that people with disabilities are likely to experience
more negative life events throughout their lives (e.g., discrimination, health problems,
and financial pressures). Although, there is no evidence that people with disabilities
are inherently less able to cope with these events than their peers without disabling
conditions, coping occurs in a social context and is conditioned by what people have to
cope with [22]. People with disabilities often experience a wider range of negative life
events or stressors [33], and these stressors tend to be more complex. In addition, the stress
they experience is often chronic and cumulative in nature, and may be magnified by factors
related to their disabling condition, such as interpersonal discrimination, and feelings of
exclusion and difference [12,13,32].
This certainly accords with the experiences of the Thalidomide survivors. As they
grow older, they are being exposed to a greater range of stressors, notably increasing
impairment, secondary health problems, changing social roles such as giving up paid
work, and the need for more assistance [5,25,26], which can have profound implications
for mental health. Healthcare practitioners need to understand these implications for all
people with early acquired disability. It should not be assumed that they get used to living
with disability and are in some way more able to cope with additional health problems [29].
Nor should it be assumed that depression is an inevitable consequence of disability: it can
be prevented, and when it does occur, treatment should be offered.
More research is needed to understand the complex relationship between early ac-
quired physical disability and depression. However, we also need to establish a better
understanding of the mental health consequences of living a long life with disability, so
that disabled people can be supported to maintain their mental well-being.
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Limitations
Respondents may not be fully representative of all UK Thalidomide survivors in terms
of severity of impairment and socioeconomic characteristics; slightly more women than
men responded to the survey and this could have had an impact on the results; those with
more vulnerable mental health may have been less likely to respond to the survey and this
could have affected the results; comparisons with the general population/other groups
with disabling conditions are limited.
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